B. Riley Issues Pessimistic Forecast for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its price objective dropped by analysts at B. Riley from $9.00 to $7.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley’s price target indicates a potential upside of 231.75% from the company’s previous close.

PDSB has been the topic of a number of other research reports. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Friday, November 15th. Finally, StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $2.11 on Monday. The stock’s fifty day moving average is $3.08 and its 200 day moving average is $3.18. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.68. The firm has a market capitalization of $78.94 million, a PE ratio of -1.82 and a beta of 1.93. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after acquiring an additional 37,142 shares during the last quarter. XTX Topco Ltd lifted its holdings in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after acquiring an additional 47,528 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in PDS Biotechnology by 233.3% in the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock valued at $153,000 after acquiring an additional 28,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology in the second quarter valued at approximately $146,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in PDS Biotechnology in the second quarter valued at approximately $115,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.